PHILADELPHIA, PA, USA and OXFORD, UK I December 11, 2017 I Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, submitted updated data from its completed pilot study1 of NY‑ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of autologous stem cell transplant (ASCT) presented by the main investigator at the annual ASH meeting. “Mature data from this study in multiple myeloma continues to show promising efficacy and acceptable safety,” said Rafael Amado, Adaptimmune’s Chief Medical Officer. “We have observed a high response rate, long response duration, and encouraging long‑term survival in this population of patients with poor prognosis, treatment refractory myeloma. In addition, NY-ESO SPEAR memory T-cells persist long-term and respond to antigen after more than three years post‑treatment. NY-ESO SPEAR T-cell therapy is currently being evaluated in a second study in multiple myeloma patients with or without KEYTRUDA®, all without stem cell transplant.” Long-term follow up data from the pilot study of NY-ESO in multiple myeloma in the context of ASCT During an oral presentation, Dr. Edward Stadtmauer, University of Pennsylvania Abramson Cancer Center, presented an update on all twenty-five multiple myeloma patients treated in Adaptimmune’s pilot study in the setting of ASCT. The data cut-off for this oral presentation was August 16, 2017. Overall Conclusions
Efficacy Results
Safety Results
Exploratory Endpoints
About Adaptimmune 1 This study closed for enrollment in 2015. All ongoing NY-ESO studies will ultimately transition to GSK as part of its option exercise over Adaptimmune’s NY‑ESO SPEAR T-cell therapy program that was announced in September 2017. SOURCE: Adaptimmune |
Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study
Published on: Tuesday, 12 December 2017 08:12 AM
PHILADELPHIA, PA, USA and OXFORD, UK I December 11, 2017 I Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, submitted updated data from its completed pilot study1 of NY‑ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of autologous stem cell transplant (ASCT) presented by the main investigator at the annual ASH meeting. “Mature data from this study in multiple myeloma continues to show promising efficacy and acceptable safety,” said Rafael Amado, Adaptimmune’s Chief Medical Officer. “We have observed a high response rate, long response duration, and encouraging long‑term survival in this population of patients with poor prognosis, treatment refractory myeloma. In addition, NY-ESO SPEAR memory T-cells persist long-term and respond to antigen after more than three years post‑treatment. NY-ESO SPEAR T-cell therapy is currently being evaluated in a second study in multiple myeloma patients with or without KEYTRUDA®, all without stem cell transplant.” Long-term follow up data from the pilot study of NY-ESO in multiple myeloma in the context of ASCT During an oral presentation, Dr. Edward Stadtmauer, University of Pennsylvania Abramson Cancer Center, presented an update on all twenty-five multiple myeloma patients treated in Adaptimmune’s pilot study in the setting of ASCT. The data cut-off for this oral presentation was August 16, 2017. Overall Conclusions
Efficacy Results
Safety Results
Exploratory Endpoints
About Adaptimmune 1 This study closed for enrollment in 2015. All ongoing NY-ESO studies will ultimately transition to GSK as part of its option exercise over Adaptimmune’s NY‑ESO SPEAR T-cell therapy program that was announced in September 2017. SOURCE: Adaptimmune |
Featured Reports
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe2023 Sales of Antibodies & Proteins
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeRElated News